Hypertension and Diabetes

  • Colleen Majewski
  • George L. BakrisEmail author
Reference work entry
Part of the Endocrinology book series (ENDOCR)


Hypertension is seen in most people with hypertension and accentuates cardiovascular risk and accelerates development of kidney function decline. In most cases there is a genetic predisposition to develop hypertension in people with diabetes compounded by the presence of obesity and high sodium intake. While reduction in weight and sodium intake ameliorates elevations in blood pressure in most cases medications are needed. With proper control of blood pressure to levels below 140/90 mmHg there has been a marked reduction cardiovascular events and a slowing of kidney disease progression from 10–12 ml/min/year before decline in estimated glomerular filtration rate before 1985 to 2–4 ml/min/year decline currently. Moreover, those born after 1980 with type 1 diabetes have a 40% lower risk of developing end stage kidney disease than those born previously. Treatment of hypertension depends on stage of kidney disease. A low sodium i.e., <2300 mg/d diet, at least 6–7 hours of uninterrupted sleep and weight loss are the cornerstones of therapy. Drug treatment will be much less effective if these lifestyle issues are not in place. Those with macroalbuminuria i.e., greater than 300 mg/day and a blood pressure ≥ 140/90 mmHg must be treated if with an angiotensin converting enzyme inhibitor or an angiotensin converting enzyme inhibitor as part of the regimen. In all others it is important to lower blood pressure to <140/90 mmHg and use of either a renin angiotensin system blocker, thiazide-type diuretic or calcium antagonist may be used alone or in combination.


Hypertension Nephropathy Blood pressure Diabetes 


  1. Accord Study Group, Cushman WC, Evans GW, Byington RP, Goff DC Jr, Grimm RH Jr, et al. Effects of intensive blood-pressure control in type 2 diabetes mellitus. N Engl J Med. 2010;362(17):1575–85.CrossRefGoogle Scholar
  2. Action to Control Cardiovascular Risk in Diabetes Study Group, Gerstein HC, Miller ME, Byington RP, Goff DC Jr, Bigger JT, et al. Effects of intensive glucose lowering in type 2 diabetes. N Engl J Med. 2008;358(24):2545–59.CrossRefGoogle Scholar
  3. Adrogue HJ, Madias NE. Sodium and potassium in the pathogenesis of hypertension. N Engl J Med. 2007;356(19):1966–78.PubMedCrossRefGoogle Scholar
  4. Advance Collaborative Group, Patel A, MacMahon S, Chalmers J, Neal B, Billot L, et al. Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes. N Engl J Med. 2008;358(24):2560–72.CrossRefGoogle Scholar
  5. Agarwal R, Sinha AD, Pappas MK, Ammous F. Chlorthalidone for poorly controlled hypertension in chronic kidney disease: an interventional pilot study. Am J Nephrol. 2014;39(2):171–82.PubMedCrossRefGoogle Scholar
  6. Appel LJ, Brands MW, Daniels SR, Karanja N, Elmer PJ, Sacks FM, et al. Dietary approaches to prevent and treat hypertension: a scientific statement from the American Heart Association. Hypertension. 2006;47(2):296–308.PubMedCrossRefGoogle Scholar
  7. Baker WL, Smyth LR, Riche DM, Bourret EM, Chamberlin KW, White WB. Effects of sodium-glucose co-transporter 2 inhibitors on blood pressure: a systematic review and meta-analysis. J Am Soc Hypertens. 2014;8(4):262–75 e9.PubMedCrossRefGoogle Scholar
  8. Bakris GL. The importance of blood pressure control in the patient with diabetes. Am J Med. 2004;116(Suppl 5A):30S–8S.PubMedCrossRefGoogle Scholar
  9. Bakris GL, Molitch M. Microalbuminuria as a risk predictor in diabetes: the continuing saga. Diabetes Care. 2014;37(3):867–75.PubMedCrossRefGoogle Scholar
  10. Bakris GL, Fonseca V, Katholi RE, McGill JB, Messerli FH, Phillips RA, et al. Metabolic effects of carvedilol vs metoprolol in patients with type 2 diabetes mellitus and hypertension: a randomized controlled trial. JAMA. 2004;292(18):2227–36.PubMedCrossRefGoogle Scholar
  11. Bakris G, Molitch M, Hewkin A, Kipnes M, Sarafidis P, Fakouhi K, et al. Differences in glucose tolerance between fixed-dose antihypertensive drug combinations in people with metabolic syndrome. Diabetes Care. 2006;29(12):2592–7.PubMedCrossRefGoogle Scholar
  12. Bakris GL, Pitt B, Weir MR, Freeman MW, Mayo MR, Garza D, et al. Effect of Patiromer on serum potassium level in patients with hyperkalemia and diabetic kidney disease: the AMETHYST-DN randomized clinical trial. JAMA. 2015;314(2):151–61.PubMedCrossRefGoogle Scholar
  13. Bangalore S, Kamalakkannan G, Parkar S, Messerli FH. Fixed-dose combinations improve medication compliance: a meta-analysis. Am J Med. 2007;120(8):713–9.PubMedCrossRefGoogle Scholar
  14. Bangalore S, Messerli FH, Wun CC, Zuckerman AL, DeMicco D, Kostis JB, et al. J-curve revisited: an analysis of blood pressure and cardiovascular events in the treating to new targets (TNT) trial. Eur Heart J. 2010;31(23):2897–908.PubMedCrossRefGoogle Scholar
  15. Barzilay JI, Davis BR, Pressel SL, Cutler JA, Einhorn PT, Black HR, et al. Long-term effects of incident diabetes mellitus on cardiovascular outcomes in people treated for hypertension: the ALLHAT diabetes extension study. Circ Cardiovasc Qual Outcomes. 2012;5(2):153–62.PubMedPubMedCentralCrossRefGoogle Scholar
  16. Becton LJ, Shatat IF, Flynn JT. Hypertension and obesity: epidemiology, mechanisms and clinical approach. Indian J Pediatr. 2012;79(8):1056–61.PubMedCrossRefGoogle Scholar
  17. Bengtsson K, Orho-Melander M, Lindblad U, Melander O, Bog-Hansen E, Ranstam J, et al. Polymorphism in the angiotensin converting enzyme but not in the angiotensinogen gene is associated with hypertension and type 2 diabetes: the Skaraborg hypertension and diabetes project. J Hypertens. 1999;17(11):1569–75.PubMedCrossRefGoogle Scholar
  18. Berl T, Hunsicker LG, Lewis JB, Pfeffer MA, Porush JG, Rouleau JL, et al. Impact of achieved blood pressure on cardiovascular outcomes in the Irbesartan diabetic nephropathy trial. J Am Soc Nephrol. 2005;16(7):2170–9.PubMedCrossRefGoogle Scholar
  19. Blood Pressure Lowering Treatment Trialists Collaboration, Turnbull F, Neal B, Ninomiya T, Algert C, Arima H, et al. Effects of different regimens to lower blood pressure on major cardiovascular events in older and younger adults: meta-analysis of randomised trials. BMJ. 2008;336(7653):1121–3.CrossRefGoogle Scholar
  20. Buraczynska M, Zukowski P, Buraczynska K, Mozul S, Ksiazek A. Renalase gene polymorphisms in patients with type 2 diabetes, hypertension and stroke. NeuroMolecular Med. 2011;13(4):321–7.PubMedPubMedCentralCrossRefGoogle Scholar
  21. Buse JB, Ginsberg HN, Bakris GL, Clark NG, Costa F, Eckel R, et al. Primary prevention of cardiovascular diseases in people with diabetes mellitus: a scientific statement from the American Heart Association and the American Diabetes Association. Circulation. 2007;115(1):114–26.PubMedCrossRefGoogle Scholar
  22. Calhoun DA, Jones D, Textor S, Goff DC, Murphy TP, Toto RD, et al. Resistant hypertension: diagnosis, evaluation, and treatment. A scientific statement from the American Heart Association professional education Committee of the Council for high blood pressure research. Hypertension. 2008;51(6):1403–19.PubMedCrossRefGoogle Scholar
  23. Carter BL, Einhorn PT, Brands M, He J, Cutler JA, Whelton PK, et al. Thiazide-induced dysglycemia: call for research from a working group from the national heart, lung, and blood institute. Hypertension. 2008;52(1):30–6.PubMedCrossRefGoogle Scholar
  24. Chapman N, Dobson J, Wilson S, Dahlof B, Sever PS, Wedel H, et al. Effect of spironolactone on blood pressure in subjects with resistant hypertension. Hypertension. 2007;49(4):839–45.PubMedCrossRefGoogle Scholar
  25. Cherney DZ, Perkins BA, Soleymanlou N, Maione M, Lai V, Lee A, et al. Renal hemodynamic effect of sodium-glucose cotransporter 2 inhibition in patients with type 1 diabetes mellitus. Circulation. 2014 Feb 4;129(5):587–97.PubMedCrossRefGoogle Scholar
  26. Chobanian AV, Bakris GL, Black HR, Cushman WC, Green LA, Izzo JL Jr, et al. Seventh report of the joint national committee on prevention, detection, evaluation, and treatment of high blood pressure. Hypertension. 2003;42(6):1206–52.CrossRefPubMedGoogle Scholar
  27. Chua DC, Bakris GL. Is proteinuria a plausible target of therapy? Curr Hypertens Rep. 2004;6(3):177–81.PubMedCrossRefGoogle Scholar
  28. Cooper-DeHoff RM, Gong Y, Handberg EM, Bavry AA, Denardo SJ, Bakris GL, et al. Tight blood pressure control and cardiovascular outcomes among hypertensive patients with diabetes and coronary artery disease. JAMA. 2010;304(1):61–8.PubMedPubMedCentralCrossRefGoogle Scholar
  29. de Zeeuw D, Remuzzi G, Parving HH, Keane WF, Zhang Z, Shahinfar S, et al. Albuminuria, a therapeutic target for cardiovascular protection in type 2 diabetic patients with nephropathy. Circulation. 2004;110(8):921–7.PubMedCrossRefGoogle Scholar
  30. DREAM Trial Investigators, Bosch J, Yusuf S, Gerstein HC, Pogue J, Sheridan P, et al. Effect of ramipril on the incidence of diabetes. N Engl J Med. 2006;355(15):1551–62.CrossRefGoogle Scholar
  31. Egan BM, Zhao Y, Axon RN. US trends in prevalence, awareness, treatment, and control of hypertension, 1988-2008. JAMA. 2010;303(20):2043–50.PubMedCrossRefGoogle Scholar
  32. Elliott WJ, Meyer PM. Incident diabetes in clinical trials of antihypertensive drugs: a network meta-analysis. Lancet. 2007;369(9557):201–7.PubMedCrossRefGoogle Scholar
  33. Emdin CA, Rahimi K, Neal B, Callender T, Perkovic V, Patel A. Blood pressure lowering in type 2 diabetes: a systematic review and meta-analysis. JAMA. 2015;313(6):603–15.PubMedCrossRefGoogle Scholar
  34. Engeli S, Bohnke J, Gorzelniak K, Janke J, Schling P, Bader M, et al. Weight loss and the renin-angiotensin-aldosterone system. Hypertension. 2005;45(3):356–62.PubMedCrossRefPubMedCentralGoogle Scholar
  35. Estacio RO, Jeffers BW, Gifford N, Schrier RW. Effect of blood pressure control on diabetic microvascular complications in patients with hypertension and type 2 diabetes. Diabetes Care. 2000;23(Suppl 2):B54–64.PubMedPubMedCentralGoogle Scholar
  36. Flynn C, Bakris GL. Interaction between adiponectin and aldosterone. Cardiorenal Med. 2011;1(2):96–101.PubMedPubMedCentralCrossRefGoogle Scholar
  37. Gerbino PP, Shoheiber O. Adherence patterns among patients treated with fixed-dose combination versus separate antihypertensive agents. Am J Health Syst Pharm. 2007;64(12):1279–83.PubMedCrossRefPubMedCentralGoogle Scholar
  38. Giles TD, Materson BJ, Cohn JN, Kostis JB. Definition and classification of hypertension: an update. J Clin Hypertens. 2009;11(11):611–4.CrossRefGoogle Scholar
  39. Goodfriend TL, Calhoun DA. Resistant hypertension, obesity, sleep apnea, and aldosterone: theory and therapy. Hypertension. 2004;43(3):518–24.PubMedCrossRefPubMedCentralGoogle Scholar
  40. Gorzelniak K, Engeli S, Janke J, Luft FC, Sharma AM. Hormonal regulation of the human adipose-tissue renin-angiotensin system: relationship to obesity and hypertension. J Hypertens. 2002;20(5):965–73.PubMedCrossRefPubMedCentralGoogle Scholar
  41. Gradman AH, Basile JN, Carter BL, Bakris GL, Materson BJ, Black HR, et al. Combination therapy in hypertension. J Am Soc Hypertens. 2010;4(2):90–8.PubMedCrossRefPubMedCentralGoogle Scholar
  42. Groop LC, Kankuri M, Schalin-Jantti C, Ekstrand A, Nikula-Ijas P, Widen E, et al. Association between polymorphism of the glycogen synthase gene and non-insulin-dependent diabetes mellitus. N Engl J Med. 1993;328(1):10–4.PubMedCrossRefPubMedCentralGoogle Scholar
  43. Hajjar I, Kotchen TA. Trends in prevalence, awareness, treatment, and control of hypertension in the United States, 1988-2000. JAMA. 2003;290(2):199–206.PubMedCrossRefPubMedCentralGoogle Scholar
  44. Hall JE. The kidney, hypertension, and obesity. Hypertension. 2003;41(3 Pt 2):625–33.PubMedPubMedCentralGoogle Scholar
  45. Hansson L, Zanchetti A, Carruthers SG, Dahlof B, Elmfeldt D, Julius S, et al. Effects of intensive blood-pressure lowering and low-dose aspirin in patients with hypertension: principal results of the hypertension optimal treatment (HOT) randomised trial. HOT study group. Lancet. 1998;351(9118):1755–62.PubMedCrossRefPubMedCentralGoogle Scholar
  46. He FJ, Markandu ND, MacGregor GA. Importance of the renin system for determining blood pressure fall with acute salt restriction in hypertensive and normotensive whites. Hypertension. 2001;38(3):321–5.PubMedCrossRefGoogle Scholar
  47. Hwang HR, Lee JG, Lee S, Cha KS, Choi JH, Jeong DW, et al. The relationship between hypertension and sleep duration: an analysis of the fifth Korea National Health and nutrition examination survey (KNHANES V-3). Clinical Hypertens. 2015;21:8.CrossRefGoogle Scholar
  48. Hypertension in Diabetes Study Group. Hypertension in diabetes study (HDS): I. Prevalence of hypertension in newly presenting type 2 diabetic patients and the association with risk factors for cardiovascular and diabetic complications. J Hypertens. 1993;11(3):309–17.CrossRefGoogle Scholar
  49. Ibsen H, Wachtell K, Olsen MH, Borch-Johnsen K, Lindholm LH, Mogensen CE, et al. Does albuminuria predict cardiovascular outcome on treatment with losartan versus atenolol in hypertension with left ventricular hypertrophy? A LIFE substudy. J Hypertens. 2004;22(9):1805–11.PubMedCrossRefGoogle Scholar
  50. International Consortium for Blood Pressure Genome-Wide Association Studies, Ehret GB, Munroe PB, Rice KM, Bochud M, Johnson AD, et al. Genetic variants in novel pathways influence blood pressure and cardiovascular disease risk. Nature. 2011;478(7367):103–9.CrossRefGoogle Scholar
  51. James PA, Oparil S, Carter BL, Cushman WC, Dennison-Himmelfarb C, Handler J, et al. 2014 evidence-based guideline for the management of high blood pressure in adults: report from the panel members appointed to the eighth joint National Committee (JNC 8). JAMA. 2014;311(5):507–20.CrossRefPubMedGoogle Scholar
  52. Jerums G, Premaratne E, Panagiotopoulos S, MacIsaac RJ. The clinical significance of hyperfiltration in diabetes. Diabetologia. 2010 Oct;53(10):2093–104.PubMedCrossRefGoogle Scholar
  53. Kadowaki T, Kadowaki H, Rechler MM, Serrano-Rios M, Roth J, Gorden P, et al. Five mutant alleles of the insulin receptor gene in patients with genetic forms of insulin resistance. J Clin Invest. 1990;86(1):254–64.PubMedPubMedCentralCrossRefGoogle Scholar
  54. Kaiser T, Heise T, Nosek L, Eckers U, Sawicki PT. Influence of nebivolol and enalapril on metabolic parameters and arterial stiffness in hypertensive type 2 diabetic patients. J Hypertens. 2006;24(7):1397–403.PubMedCrossRefGoogle Scholar
  55. Kannel WB, Garrison RJ, Dannenberg AL. Secular blood pressure trends in normotensive persons: the Framingham study. Am Heart J. 1993;125(4):1154–8.PubMedCrossRefPubMedCentralGoogle Scholar
  56. Kearney PM, Whelton M, Reynolds K, Muntner P, Whelton PK, He J. Global burden of hypertension: analysis of worldwide data. Lancet. 2005;365(9455):217–23.PubMedCrossRefPubMedCentralGoogle Scholar
  57. Kjeldsen SE, Berge E, Bangalore S, Messerli FH, Mancia G, Holzhauer B, et al. No evidence for a J-shaped curve in treated hypertensive patients with increased cardiovascular risk: the VALUE trial. Blood Press. 2016;25(2):83–92.PubMedCrossRefPubMedCentralGoogle Scholar
  58. Knowler WC, Barrett-Connor E, Fowler SE, Hamman RF, Lachin JM, Walker EA, et al. Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin. N Engl J Med. 2002;346(6):393–403.CrossRefPubMedPubMedCentralGoogle Scholar
  59. Kosiborod M, Rasmussen HS, Lavin P, Qunibi WY, Spinowitz B, Packham D, et al. Effect of sodium zirconium cyclosilicate on potassium lowering for 28 days among outpatients with hyperkalemia: the HARMONIZE randomized clinical trial. JAMA. 2014;312(21):2223–33.PubMedCrossRefPubMedCentralGoogle Scholar
  60. Kostis JB, Wilson AC, Freudenberger RS, Cosgrove NM, Pressel SL, Davis BR, et al. Long-term effect of diuretic-based therapy on fatal outcomes in subjects with isolated systolic hypertension with and without diabetes. Am J Cardiol. 2005;95(1):29–35.PubMedCrossRefGoogle Scholar
  61. Kraja AT, Vaidya D, Pankow JS, Goodarzi MO, Assimes TL, Kullo IJ, et al. A bivariate genome-wide approach to metabolic syndrome: STAMPEED consortium. Diabetes. 2011;60(4):1329–39.PubMedPubMedCentralCrossRefGoogle Scholar
  62. Krug AW, Ehrhart-Bornstein M. Aldosterone and metabolic syndrome: is increased aldosterone in metabolic syndrome patients an additional risk factor? Hypertension. 2008;51(5):1252–8.PubMedCrossRefGoogle Scholar
  63. Lazich I, Bakris GL. Prediction and management of hyperkalemia across the spectrum of chronic kidney disease. Semin Nephrol. 2014;34(3):333–9.PubMedCrossRefGoogle Scholar
  64. Lewis EJ, Hunsicker LG, Clarke WR, Berl T, Pohl MA, Lewis JB, et al. Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes. N Engl J Med. 2001;345(12):851–60.PubMedCrossRefGoogle Scholar
  65. Liu G, Hitomi H, Hosomi N, Lei B, Nakano D, Deguchi K, et al. Mechanical stretch augments insulin-induced vascular smooth muscle cell proliferation by insulin-like growth factor-1 receptor. Exp Cell Res. 2011;317(17):2420–8.PubMedCrossRefGoogle Scholar
  66. Liu Y, Wheaton AG, Chapman DP, Cunningham TJ, Lu H, Croft JB. Prevalence of healthy sleep duration among adults - United States, 2014. MMWR Morb Mortal Wkly Rep. 2016;65(6):137–41.PubMedCrossRefGoogle Scholar
  67. Malatiali S, Francis I, Barac-Nieto M. Phlorizin prevents glomerular hyperfiltration but not hypertrophy in diabetic rats. Exp Diabetes Res. 2008;2008:305403.PubMedPubMedCentralCrossRefGoogle Scholar
  68. Mancia G, Grassi G, Zanchetti A. New-onset diabetes and antihypertensive drugs. J Hypertens. 2006;24(1):3–10.PubMedCrossRefGoogle Scholar
  69. Mancia G, De Backer G, Dominiczak A, Cifkova R, Fagard R, Germano G, et al. 2007 ESH-ESC practice guidelines for the Management of Arterial Hypertension: ESH-ESC task force on the Management of Arterial Hypertension. J Hypertens. 2007a;25(9):1751–62.PubMedCrossRefGoogle Scholar
  70. Mancia G, De Backer G, Dominiczak A, Cifkova R, Fagard R, Germano G, et al. Guidelines for the Management of Arterial Hypertension: the task force for the Management of Arterial Hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). J Hypertens. 2007b;25(6):1105–87.CrossRefPubMedGoogle Scholar
  71. Mann JF, Schmieder RE, McQueen M, Dyal L, Schumacher H, Pogue J, et al. Renal outcomes with telmisartan, ramipril, or both, in people at high vascular risk (the ONTARGET study): a multicentre, randomised, double-blind, controlled trial. Lancet. 2008;372(9638):547–53.PubMedCrossRefGoogle Scholar
  72. Margolis KL, O’Connor PJ, Morgan TM, Buse JB, Cohen RM, Cushman WC, et al. Outcomes of combined cardiovascular risk factor management strategies in type 2 diabetes: the ACCORD randomized trial. Diabetes Care. 2014;37(6):1721–8.PubMedPubMedCentralCrossRefGoogle Scholar
  73. Massiera F, Bloch-Faure M, Ceiler D, Murakami K, Fukamizu A, Gasc JM, et al. Adipose angiotensinogen is involved in adipose tissue growth and blood pressure regulation. FASEB J. 2001;15(14):2727–9.PubMedCrossRefGoogle Scholar
  74. Morris RC Jr, Sebastian A, Forman A, Tanaka M, Schmidlin O. Normotensive salt sensitivity: effects of race and dietary potassium. Hypertension. 1999;33(1):18–23.PubMedCrossRefGoogle Scholar
  75. Must A, Spadano J, Coakley EH, Field AE, Colditz G, Dietz WH. The disease burden associated with overweight and obesity. JAMA. 1999;282(16):1523–9.PubMedCrossRefGoogle Scholar
  76. Nag S, Bilous R, Kelly W, Jones S, Roper N, Connolly V. All-cause and cardiovascular mortality in diabetic subjects increases significantly with reduced estimated glomerular filtration rate (eGFR): 10 years’ data from the south tees diabetes mortality study. Diabet Med. 2007;24(1):10–7.PubMedCrossRefGoogle Scholar
  77. National Kidney Foundation. KDOQI Clinical practice guidelines and clinical practice recommendations for diabetes and chronic kidney disease. Am J Kidney Dis. 2007;49(2 Suppl 2):S12–154.Google Scholar
  78. Neter JE, Stam BE, Kok FJ, Grobbee DE, Geleijnse JM. Influence of weight reduction on blood pressure: a meta-analysis of randomized controlled trials. Hypertension. 2003;42(5):878–84.PubMedCrossRefGoogle Scholar
  79. Nishizaka MK, Zaman MA, Calhoun DA. Efficacy of low-dose spironolactone in subjects with resistant hypertension. Am J Hypertens. 2003;16(11 Pt 1):925–30.PubMedCrossRefGoogle Scholar
  80. Ojima A, Matsui T, Nishino Y, Nakamura N, Yamagishi S. Empagliflozin, an inhibitor of sodium-glucose cotransporter 2 exerts anti-inflammatory and Antifibrotic effects on experimental diabetic nephropathy partly by suppressing AGEs-receptor Axis. Horm Metab Res. 2015;47(9):686–92.PubMedCrossRefGoogle Scholar
  81. Oliva RV, Bakris GL. Blood pressure effects of sodium-glucose co-transport 2 (SGLT2) inhibitors. J Am Soc Hypertens. 2014;8(5):330–9.PubMedCrossRefGoogle Scholar
  82. Ortola FV, Ballermann BJ, Anderson S, Mendez RE, Brenner BM. Elevated plasma atrial natriuretic peptide levels in diabetic rats. Potential mediator of hyperfiltration. J Clin Invest. 1987;80(3):670–4.PubMedPubMedCentralCrossRefGoogle Scholar
  83. Parving HH, Brenner BM, McMurray JJ, de Zeeuw D, Haffner SM, Solomon SD, et al. Cardiorenal end points in a trial of aliskiren for type 2 diabetes. N Engl J Med. 2012;367(23):2204–13.PubMedCrossRefGoogle Scholar
  84. Patel SK, Wai B, Ord M, MacIsaac RJ, Grant S, Velkoska E, et al. Association of ACE2 genetic variants with blood pressure, left ventricular mass, and cardiac function in Caucasians with type 2 diabetes. Am J Hypertens. 2012;25(2):216–22.PubMedCrossRefGoogle Scholar
  85. Peralta CA, Norris KC, Li S, Chang TI, Tamura MK, Jolly SE, et al. Blood pressure components and end-stage renal disease in persons with chronic kidney disease: the kidney early evaluation program (KEEP). Arch Intern Med. 2012;172(1):41–7.PubMedPubMedCentralCrossRefGoogle Scholar
  86. Perkovic V, Rodgers A. Redefining blood-pressure targets--SPRINT starts the marathon. N Engl J Med. 2015;373(22):2175–8.PubMedCrossRefGoogle Scholar
  87. Powell DR, DaCosta CM, Gay J, Ding ZM, Smith M, Greer J, et al. Improved glycemic control in mice lacking Sglt1 and Sglt2. Am J Physiol Endocrinol Metab. 2013;304(2):E117–30.PubMedCrossRefGoogle Scholar
  88. Pratt-Ubunama MN, Nishizaka MK, Boedefeld RL, Cofield SS, Harding SM, Calhoun DA. Plasma aldosterone is related to severity of obstructive sleep apnea in subjects with resistant hypertension. Chest. 2007;131(2):453–9.PubMedCrossRefGoogle Scholar
  89. Robles RG, Villa E, Santirso R, Martinez J, Ruilope LM, Cuesta C, et al. Effects of captopril on sympathetic activity, lipid and carbohydrate metabolism in a model of obesity-induced hypertension in dogs. Am J Hypertens. 1993;6(12):1009–15.PubMedCrossRefGoogle Scholar
  90. Sarafidis PA, Bakris GL. Antihypertensive therapy and the risk of new-onset diabetes. Diabetes Care. 2006a;29(5):1167–9.PubMedCrossRefGoogle Scholar
  91. Sarafidis PA, Bakris GL. Antihypertensive treatment with beta-blockers and the spectrum of glycaemic control. QJM. 2006b;99(7):431–6.PubMedCrossRefGoogle Scholar
  92. Sarafidis PA, Bakris GL. State of hypertension management in the United States: confluence of risk factors and the prevalence of resistant hypertension. J Clin Hypertens. 2008;10(2):130–9.CrossRefGoogle Scholar
  93. Sarafidis PA, Khosla N, Bakris GL. Antihypertensive therapy in the presence of proteinuria. Am J Kidney Dis. 2007a;49(1):12–26.PubMedCrossRefGoogle Scholar
  94. Sarafidis PA, McFarlane SI, Bakris GL. Antihypertensive agents, insulin sensitivity, and new-onset diabetes. Curr Diab Rep. 2007b;7(3):191–9.PubMedCrossRefGoogle Scholar
  95. Saseen JJ, Carter BL, Brown TE, Elliott WJ, Black HR. Comparison of nifedipine alone and with diltiazem or verapamil in hypertension. Hypertension. 1996;28(1):109–14.PubMedCrossRefGoogle Scholar
  96. Scheen AJ. Pharmacokinetics, pharmacodynamics and clinical use of SGLT2 inhibitors in patients with type 2 diabetes mellitus and chronic kidney disease. Clin Pharmacokinet. 2015a;54(7):691–708.PubMedCrossRefGoogle Scholar
  97. Scheen AJ. Pharmacodynamics, efficacy and safety of sodium-glucose co-transporter type 2 (SGLT2) inhibitors for the treatment of type 2 diabetes mellitus. Drugs. 2015b;75(1):33–59.PubMedCrossRefGoogle Scholar
  98. Sharma AM. Adipose tissue: a mediator of cardiovascular risk. Int J Obes Relat Metabol Disord. 2002;26(Suppl 4):S5–7.CrossRefGoogle Scholar
  99. Sharma AM. Obesity and cardiovascular risk. Growth Hormon IGF Res. 2003;13(Suppl A):S10–7.CrossRefGoogle Scholar
  100. Sharma AM, Janke J, Gorzelniak K, Engeli S, Luft FC. Angiotensin blockade prevents type 2 diabetes by formation of fat cells. Hypertension. 2002;40(5):609–11.PubMedCrossRefGoogle Scholar
  101. Simino J, Rao DC, Freedman BI. Novel findings and future directions on the genetics of hypertension. Curr Opin Nephrol Hypertens. 2012;21(5):500–7.PubMedCrossRefGoogle Scholar
  102. Sleight P, Redon J, Verdecchia P, Mancia G, Gao P, Fagard R, et al. Prognostic value of blood pressure in patients with high vascular risk in the ongoing Telmisartan alone and in combination with Ramipril global endpoint trial study. J Hypertens. 2009;27(7):1360–9.PubMedCrossRefGoogle Scholar
  103. So WY, Kong AP, Ma RC, Ozaki R, Szeto CC, Chan NN, et al. Glomerular filtration rate, cardiorenal end points, and all-cause mortality in type 2 diabetic patients. Diabetes Care. 2006;29(9):2046–52.PubMedCrossRefGoogle Scholar
  104. Sowers JR, Nyby M, Stern N, Beck F, Baron S, Catania R, et al. Blood pressure and hormone changes associated with weight reduction in the obese. Hypertension. 1982;4(5):686–91.PubMedCrossRefGoogle Scholar
  105. SPRINT Research Group, Wright JT Jr, Williamson JD, Whelton PK, Snyder JK, Sink KM, et al. A randomized trial of intensive versus standard blood-pressure control. N Engl J Med. 2015;373(22):2103–16.CrossRefGoogle Scholar
  106. Staessen JA, Li Y, Thijs L, Wang JG. Blood pressure reduction and cardiovascular prevention: an update including the 2003-2004 secondary prevention trials. Hypertens Res. 2005;28(5):385–407.PubMedCrossRefGoogle Scholar
  107. Stamler J, Stamler R, Neaton JD. Blood pressure, systolic and diastolic, and cardiovascular risks. US population data. Arch Intern Med. 1993;153(5):598–615.CrossRefGoogle Scholar
  108. Standards of Medical Care in Diabetes-2016. Summary of revisions. Diabetes Care. 2016;39(Suppl 1):S4–5.Google Scholar
  109. Stevens VJ, Obarzanek E, Cook NR, Lee IM, Appel LJ, Smith West D, et al. Long-term weight loss and changes in blood pressure: results of the trials of hypertension prevention, phase II. Ann Intern Med. 2001;134(1):1–11.PubMedCrossRefGoogle Scholar
  110. Thompson D, Edelsberg J, Colditz GA, Bird AP, Oster G. Lifetime health and economic consequences of obesity. Arch Intern Med. 1999;159(18):2177–83.PubMedCrossRefGoogle Scholar
  111. Thomson SC, Rieg T, Miracle C, Mansoury H, Whaley J, Vallon V, et al. Acute and chronic effects of SGLT2 blockade on glomerular and tubular function in the early diabetic rat. Am J Physiol Regul Integr Comp Physiol. 2012;302(1):R75–83.PubMedCrossRefGoogle Scholar
  112. Tian F, Luo R, Zhao Z, Wu Y, Ban D. Blockade of the RAS increases plasma adiponectin in subjects with metabolic syndrome and enhances differentiation and adiponectin expression of human preadipocytes. Exp Clin Endocrinol Diabetes. 2010;118(4):258–65.PubMedCrossRefGoogle Scholar
  113. Tuck ML, Sowers J, Dornfeld L, Kledzik G, Maxwell M. The effect of weight reduction on blood pressure, plasma renin activity, and plasma aldosterone levels in obese patients. N Engl J Med. 1981;304(16):930–3.PubMedCrossRefGoogle Scholar
  114. UKPDS Group. Tight blood pressure control and risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 38. UK prospective diabetes study group. BMJ. 1998;317(7160):703–13.CrossRefGoogle Scholar
  115. van Ittersum FJ, de Man AM, Thijssen S, de Knijff P, Slagboom E, Smulders Y, et al. Genetic polymorphisms of the renin-angiotensin system and complications of insulin-dependent diabetes mellitus. Nephrol Dialys Transplant. 2000;15(7):1000–7.CrossRefGoogle Scholar
  116. Weber MA, Bakris GL, Jamerson K, Weir M, Kjeldsen SE, Devereux RB, et al. Cardiovascular events during differing hypertension therapies in patients with diabetes. J Am Coll Cardiol. 2010;56(1):77–85.PubMedCrossRefGoogle Scholar
  117. Weber MA, Jamerson K, Bakris GL, Weir MR, Zappe D, Zhang Y, et al. Effects of body size and hypertension treatments on cardiovascular event rates: subanalysis of the ACCOMPLISH randomised controlled trial. Lancet. 2013;381(9866):537–45.PubMedCrossRefGoogle Scholar
  118. Wedler B, Wiersbitzki M, Gruska S, Wolf E, Luft FC. Definitions and characteristics of salt-sensitivity and resistance of blood pressure: should the diagnosis depend on diastolic blood pressure? Clin Experiment Hypertens Part A. 1992;14(6):1037–49.CrossRefGoogle Scholar
  119. Whelton PK, Barzilay J, Cushman WC, Davis BR, Iiamathi E, Kostis JB, et al. Clinical outcomes in antihypertensive treatment of type 2 diabetes, impaired fasting glucose concentration, and normoglycemia: antihypertensive and lipid-lowering treatment to prevent heart attack trial (ALLHAT). Arch Intern Med. 2005;165(12):1401–9.PubMedCrossRefGoogle Scholar
  120. Wobeto VP, Pinho Pda C, Souza JR, Zaccariotto TR, Zonati Mde F. Haptoglobin genotypes and refractory hypertension in type 2 diabetes mellitus patients. Arq Bras Cardiol. 2011;97(4):338–45.PubMedCrossRefGoogle Scholar
  121. Wright EM, Loo DD, Hirayama BA. Biology of human sodium glucose transporters. Physiol Rev. 2011 Apr;91(2):733–94.PubMedCrossRefGoogle Scholar
  122. Wu Y, Xu J, Velazquez H, Wang P, Li G, Liu D, et al. Renalase deficiency aggravates ischemic myocardial damage. Kidney Int. 2011;79(8):853–60.PubMedCrossRefGoogle Scholar
  123. Xie X, Atkins E, Lv J, Bennett A, Neal B, Ninomiya T, et al. Effects of intensive blood pressure lowering on cardiovascular and renal outcomes: updated systematic review and meta-analysis. Lancet. 2016;387(10017):435–43.PubMedCrossRefGoogle Scholar
  124. Xu J, Li G, Wang P, Velazquez H, Yao X, Li Y, et al. Renalase is a novel, soluble monoamine oxidase that regulates cardiac function and blood pressure. J Clin Invest. 2005;115(5):1275–80.PubMedPubMedCentralCrossRefGoogle Scholar
  125. Yamout H, Perkovic V, Davies M, Woo V, de Zeeuw D, Mayer C, et al. Efficacy and safety of canagliflozin in patients with type 2 diabetes and stage 3 nephropathy. Am J Nephrol. 2014;40(1):64–74.PubMedCrossRefGoogle Scholar
  126. Yatabe MS, Yatabe J, Yoneda M, Watanabe T, Otsuki M, Felder RA, et al. Salt sensitivity is associated with insulin resistance, sympathetic overactivity, and decreased suppression of circulating renin activity in lean patients with essential hypertension. Am J Clin Nutr. 2010;92(1):77–82.PubMedCrossRefGoogle Scholar
  127. Zambrowicz B, Lapuerta P, Strumph P, Banks P, Wilson A, Ogbaa I, et al. LX4211 therapy reduces postprandial glucose levels in patients with type 2 diabetes mellitus and renal impairment despite low urinary glucose excretion. Clin Ther. 2015;37(1):71–82 e12.PubMedCrossRefGoogle Scholar

Copyright information

© Springer International Publishing AG, part of Springer Nature 2018

Authors and Affiliations

  1. 1.ASH Comprehensive Hypertension Center, Section of Endocrinology, Diabetes and MetabolismThe University of Chicago MedicineChicagoUSA

Personalised recommendations